BNGO Bionano Genomics Inc
Price (delayed)
$4.3
Market cap
$12.93M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$88.13
Enterprise value
$30.65M
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for
Highlights
The EPS has soared by 78% YoY and by 37% QoQ
The company's net income has surged by 52% YoY and by 18% QoQ
BNGO's gross margin has surged by 167% since the previous quarter but it has dropped by 95% year-on-year
Bionano Genomics's gross profit has soared by 163% from the previous quarter but it has plunged by 96% YoY
BNGO's equity has plunged by 63% YoY and by 28% from the previous quarter
BNGO's quick ratio is down by 38% year-on-year and by 20% since the previous quarter
Key stats
What are the main financial stats of BNGO
Market
Valuations
Earnings
Shares outstanding
3.01M
Market cap
$12.93M
Enterprise value
$30.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.21
Price to sales (P/S)
0.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1
Revenue
$30.78M
Gross profit
$380,000
Operating income
-$103.98M
Net income
-$112.02M
EBIT
-$111.98M
EBITDA
-$97.88M
Free cash flow
-$69.03M
Per share
Balance sheet
Liquidity
EPS
-$88.13
EPS diluted
-$88.13
Free cash flow per share
-$54.31
Book value per share
$20.81
Revenue per share
$24.21
TBVPS
$52.69
Total assets
$76.67M
Total liabilities
$41.3M
Debt
$27.3M
Equity
$35.38M
Working capital
$2.15M
Debt to equity
0.77
Current ratio
1.06
Quick ratio
0.69
Net debt/EBITDA
-0.18
Margins
Efficiency
Dividend
EBITDA margin
-318%
Gross margin
1.2%
Net margin
-364%
Operating margin
-337.9%
Return on assets
-99.3%
Return on equity
-181.1%
Return on invested capital
-170.9%
Return on capital employed
-284.8%
Return on sales
-363.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BNGO stock price
How has the Bionano Genomics stock price performed over time
Intraday
1.18%
1 week
6.17%
1 month
30.3%
1 year
-90.56%
YTD
-75.14%
QTD
54.12%
Financial performance
How have Bionano Genomics's revenue and profit performed over time
Revenue
$30.78M
Gross profit
$380,000
Operating income
-$103.98M
Net income
-$112.02M
Gross margin
1.2%
Net margin
-364%
BNGO's gross margin has surged by 167% since the previous quarter but it has dropped by 95% year-on-year
Bionano Genomics's gross profit has soared by 163% from the previous quarter but it has plunged by 96% YoY
BNGO's operating income has soared by 52% YoY and by 11% from the previous quarter
The company's net income has surged by 52% YoY and by 18% QoQ
Growth
What is Bionano Genomics's growth rate over time
Valuation
What is Bionano Genomics stock price valuation
P/E
N/A
P/B
0.21
P/S
0.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1
The EPS has soared by 78% YoY and by 37% QoQ
BNGO's price to book (P/B) is 94% lower than its 5-year quarterly average of 3.2 and 71% lower than its last 4 quarters average of 0.7
BNGO's equity has plunged by 63% YoY and by 28% from the previous quarter
The P/S is 99% below the 5-year quarterly average of 35.4 and 85% below the last 4 quarters average of 1.2
Bionano Genomics's revenue has decreased by 15% YoY and by 8% QoQ
Efficiency
How efficient is Bionano Genomics business performance
The ROS has increased by 43% YoY and by 11% QoQ
Bionano Genomics's return on equity has decreased by 29% YoY and by 2.7% QoQ
Bionano Genomics's ROIC has decreased by 12% from the previous quarter but it has increased by 11% YoY
Bionano Genomics's return on assets has decreased by 8% QoQ and by 2.5% YoY
Dividends
What is BNGO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BNGO.
Financial health
How did Bionano Genomics financials performed over time
BNGO's total assets is 86% greater than its total liabilities
The total liabilities has dropped by 65% year-on-year but it has increased by 7% since the previous quarter
BNGO's total assets has dropped by 64% year-on-year and by 12% since the previous quarter
Bionano Genomics's debt is 23% less than its equity
The debt to equity has soared by 67% since the previous quarter but it has declined by 7% year-on-year
Bionano Genomics's debt has plunged by 66% YoY but it has increased by 22% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.